Discovery medicine · 2025
Nesfatin-1 Suppresses Inflammation in Bronchopulmonary Dysplasia by Regulating HMGB-1/TLR4/p65/NLRP3 Signaling Pathway.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Xiaoting, Luo Gang, Lou Feifeng
Аннотация
BACKGROUND: Bronchopulmonary dysplasia (BPD) is a common respiratory disease in premature infants. Nesfatin-1 is considered for the treatment of BPD. This study aimed to explore the anti-inflammatory effect of nesfatin-1 in the treatment of BPD.
METHODS: Hyperoxia-induced newborn rats and transfected primary type II alveolar epithelial cells (AECIIs) were used to evaluate nesfatin-1's efficacy in treating BPD. Lung damage was assessed by means of wet-dry ratio measurement, Hematoxylin and Eosin staining, Masson staining, Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining, and Western blotting. Interleukin 6 (Il-6), tumor necrosis factor alpha (Tnf-α), and interleukin 1β (Il-1β) levels were measured by Enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (qPCR). Neutrophils in bronchoalveolar lavage fluid were counted. High mobility group box 1 (HMGB-1), Toll-like receptor 4 (TLR4), nuclear factor kappa-light-chain-enhancer of activated B cells p65 subunit (p65), and NOD-like receptor family pyrin domain containing 3 (NLRP3) expressions were analyzed using Western blotting, while NLRP3 expression was detected through immunohistochemistry. AECIIs' viability, apoptosis, and reactive oxygen species (ROS) levels were assessed using cell counting kit-8 (CCK8), flow cytometry, and immunofluorescence, respectively. An immunofluorescence approach was used to detect surfactant protein C and ROS levels.
RESULTS: In vivo, nesfatin-1 treatment significantly reduced the lung wet-dry ratio, increased the body weight of rats, inhibited apoptosis, alleviated lung damage, decreased inflammation, and lowered neutrophil counts (p < 0.05). In vitro, nesfatin-1 enhanced cell viability, inhibited apoptosis, decreased ROS levels (p < 0.01) and decreased mRNA levels of Il-6, Tnf-α, and Il-1β (p < 0.05) while increasing Il-10 mRNA (p < 0.01). In in vivo and in vitro scenarios, nesfatin-1 inhibited HMGB-1, TLR4, p65, and NLRP3 protein expression (p < 0.05). In hyperoxia cells, Hmgb-1 silencing showed similar results to those of nesfatin-1 treatment, while Hmgb-1 overexpression antagonized the effects of nesfatin-1 treatment.
CONCLUSION: This study showed that nesfatin-1 reduces neutrophils and suppresses inflammation via the HMGB-1/TLR4/Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB)/NLRP3 pathway, suggesting its potential clinical application in the treatment of BPD.
METHODS: Hyperoxia-induced newborn rats and transfected primary type II alveolar epithelial cells (AECIIs) were used to evaluate nesfatin-1's efficacy in treating BPD. Lung damage was assessed by means of wet-dry ratio measurement, Hematoxylin and Eosin staining, Masson staining, Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining, and Western blotting. Interleukin 6 (Il-6), tumor necrosis factor alpha (Tnf-α), and interleukin 1β (Il-1β) levels were measured by Enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (qPCR). Neutrophils in bronchoalveolar lavage fluid were counted. High mobility group box 1 (HMGB-1), Toll-like receptor 4 (TLR4), nuclear factor kappa-light-chain-enhancer of activated B cells p65 subunit (p65), and NOD-like receptor family pyrin domain containing 3 (NLRP3) expressions were analyzed using Western blotting, while NLRP3 expression was detected through immunohistochemistry. AECIIs' viability, apoptosis, and reactive oxygen species (ROS) levels were assessed using cell counting kit-8 (CCK8), flow cytometry, and immunofluorescence, respectively. An immunofluorescence approach was used to detect surfactant protein C and ROS levels.
RESULTS: In vivo, nesfatin-1 treatment significantly reduced the lung wet-dry ratio, increased the body weight of rats, inhibited apoptosis, alleviated lung damage, decreased inflammation, and lowered neutrophil counts (p < 0.05). In vitro, nesfatin-1 enhanced cell viability, inhibited apoptosis, decreased ROS levels (p < 0.01) and decreased mRNA levels of Il-6, Tnf-α, and Il-1β (p < 0.05) while increasing Il-10 mRNA (p < 0.01). In in vivo and in vitro scenarios, nesfatin-1 inhibited HMGB-1, TLR4, p65, and NLRP3 protein expression (p < 0.05). In hyperoxia cells, Hmgb-1 silencing showed similar results to those of nesfatin-1 treatment, while Hmgb-1 overexpression antagonized the effects of nesfatin-1 treatment.
CONCLUSION: This study showed that nesfatin-1 reduces neutrophils and suppresses inflammation via the HMGB-1/TLR4/Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB)/NLRP3 pathway, suggesting its potential clinical application in the treatment of BPD.